Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative lipid nanoparticle system capable of delivering messenger RNA (mRNA) directly to the brain via intravenous injection. This advancement addresses a long-standing challenge posed by the protective blood-brain barrier, which has traditionally restricted the entry of therapeutic agents into the central nervous system.

The study demonstrates the potential of this technology to revolutionise treatment options for conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), brain cancer, and drug addiction. Conducted in both mouse models and isolated human brain tissue, the findings highlight the feasibility of using lipid nanoparticles to transport mRNA into the brain, overcoming a major limitation in neurological drug delivery.